Table 3 Total one-year outcome and incremental cost-effectiveness ratio (ICER) for basic and scenario model
From: Cost-effectiveness of CTA, MRA and DSA in patients with non-traumatic subarachnoid haemorrhage
|  | Costs (€) | (95 % CI) | QALYs | (95 % CI) |  |  |
|---|---|---|---|---|---|---|
Basic model | Â | Â | ||||
 DSA | 39,808 | (37,182 ; 42,663) | 0.6039 | (0.5761 ; 0.6327) |  |  |
 CTA | 40,748 | (37,937 ; 43,831) | 0.5983 | (0.5704 ; 0.6278) |  |  |
 MRA | 41,814 | (38,730 ; 45,146) | 0.5947 | (0.5674 ; 0.6237) |  |  |
Scenario model | Â | Â | ||||
 DSA | 39,808 | (36,982 ; 42,414) | 0.6039 | (0.5771 ; 0.6333) |  |  |
 CTA | 39,767 | (36,903 ; 42,402) | 0.6039 | (0.5771 ; 0.6333) |  |  |
 MRA | 39,851 | (37,003 ; 42,486) | 0.6039 | (0.5771 ; 0.6333) |  |  |
|  | Incremental costs (€) | (95 % CI) | Incremental QALYs | (95 % CI) | ICER (€ per QALY) | Comparator |
Basic model | ||||||
 DSA |  |  |  |  |  |  |
 CTA | 940 | (10 ; 2,122) | −0.006 | (−0.003 ; −0.009) | Dominated | DSA |
 MRA | 2,007 | (604 ; 3,767) | −0.009 | (−0.005 ; −0.015) | Dominated | DSA |
Scenario model | ||||||
 DSA |  |  |  |  |  |  |
 CTA | −40 | (−103 ; 20) | 0.000 | (0.000 ; 0.000) | Dominant | DSA |
 MRA | 84 | (−15 ; 98) | 0.000 | (0.000 ; 0.000) | Dominated | CTA |